1
|
Fratzl M, Bigotte P, Gorbenkov R, Goubet G, Halfon P, Kauffmann P, Kirk D, Masse V, Payet-Burin X, Ramel O, Delshadi S. Magnetically localized and wash-free fluorescent immuno-assay: From a research platform (MLFIA) to a multiplexed POC system (MagIA). SLAS Technol 2024; 29:100119. [PMID: 38302059 DOI: 10.1016/j.slast.2024.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Revised: 12/21/2023] [Accepted: 01/23/2024] [Indexed: 02/03/2024]
Abstract
Sexually transmitted infections (STI) remain one of the world's public health priorities: Nearly 400 million people are infected not only in emerging, but also in western countries. HIV, HBV and HCV share common infection pathways; thus these 3 diseases are recommended to be tested at the same time. However, this combined approach is currently mainly available in laboratories, and seldomly at the Point-of-care (POC). Consequently, there is a need for a STI screening POC platform with laboratory-like performance. Such a platform should be autonomous and portable and enable multiplexed screening from capillary blood. The previously developed and introduced MLFIA (Magnetically Localized and wash-free Fluorescent Immuno-Assay) technology has the potential to address these needs, as the MLFIA 18-chamber microfluidic cartridge and the MLFIA Analyzer were previously characterized and evaluated with plasma and serum from patients infected with HIV, Hepatitis B (Hep B) or C (Hep C). Here, we present the efforts to transfer this research platform (MLFIA) to a fully integrated multi-analysis solution (MagIA). First, we present the design changes of the consumable enabling to perform multiple assays in parallel, a fast filling of the cartridge with patient samples, and a homogeneous reagent/sample incubation. Second, we describe the development a piezoelectric actuator integrated into the Analyzer: this mixing module allows for an automated, fully integrated and portable workflow, with homogeneous in-situ mixing capabilities. The obtained MagIA platform was further characterized and validated for immunoassays (LOD, cartridge stability over time), using various biological models including OVA and IgG. We discuss the performances of the MLFIA and MagIA platforms for the detection of HIV / Hep B / Hep C using results from 102 patient plasma samples. Lastly, we assessed the compatibility of the MagIA platform with veinous and capillary blood samples as a final step towards its POC validation.
Collapse
Affiliation(s)
- M Fratzl
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France
| | - P Bigotte
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France
| | - R Gorbenkov
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France
| | - G Goubet
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France
| | - P Halfon
- Hopital Europeen, Laboratoire Alphabio-Biogroup, Marseille 13003, France
| | - P Kauffmann
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France
| | - D Kirk
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France
| | - V Masse
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France
| | - X Payet-Burin
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France
| | - O Ramel
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France
| | - S Delshadi
- MagIA diagnostics, 15 rue Maréchal Leclerc, Échirolles 38130, France.
| |
Collapse
|
2
|
Augustine S, Chinnamani MV, Mun CW, Shin JY, Trung TQ, Hong SJ, Huyen LTN, Lee EH, Lee SH, Rha JJ, Jung S, Lee Y, Park SG, Lee NE. Metal-enhanced fluorescence biosensor integrated in capillary flow-driven microfluidic cartridge for highly sensitive immunoassays. Biosens Bioelectron 2024; 248:115987. [PMID: 38176256 DOI: 10.1016/j.bios.2023.115987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Revised: 12/17/2023] [Accepted: 12/27/2023] [Indexed: 01/06/2024]
Abstract
Point-of-care testing (POCT) for low-concentration protein biomarkers remains challenging due to limitations in biosensor sensitivity and platform integration. This study addresses this gap by presenting a novel approach that integrates a metal-enhanced fluorescence (MEF) biosensor within a capillary flow-driven microfluidic cartridge (CFMC) for the ultrasensitive detection of the Parkinson's disease biomarker, aminoacyl-tRNA synthetase complex interacting multi-functional protein 2 (AIMP-2). Crucial point to this approach is the orientation-controlled immobilization of capture antibody on a nanodimple-structured MEF substrate within the CFMC. This strategy significantly enhances fluorescence signals without quenching, enabling accurate quantification of low-concentration AIMP-2 using a simple digital fluorescence microscope with a light-emitting diode excitation source and a digital camera. The resulting platform exhibits exceptional sensitivity, achieving a limit of detection in the pg/mL range for AIMP-2 in human serum. Additionally, the CFMC design incorporates a capillary-driven passive sample transport mechanism, eliminating the need for external pumps and further simplifying the detection process. Overall, this work demonstrates the successful integration of MEF biosensing with capillary microfluidics for point-of-care applications.
Collapse
Affiliation(s)
- Shine Augustine
- School of Advanced Materials Science & Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea
| | - Mottour Vinayagam Chinnamani
- School of Advanced Materials Science & Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea
| | - Chae Won Mun
- Nano-Bio Convergence Department, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea
| | - Jeong-Yong Shin
- Division of Pharmacology, Department of Molecular Cell Biology, Samsung, Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Gyeonggi-do, 16419, Republic of Korea
| | - Tran Quang Trung
- School of Advanced Materials Science & Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea
| | - Seok Ju Hong
- School of Advanced Materials Science & Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea
| | - Lai Thi Ngoc Huyen
- School of Advanced Materials Science & Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea
| | - Eung Hyuk Lee
- SKKU Advanced Institute of Nanotechnology (SAINT), Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea
| | - Soo Hyun Lee
- Nano-Bio Convergence Department, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea
| | - Jong-Joo Rha
- Nano-Bio Convergence Department, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea
| | - Sunghoon Jung
- Nano-Bio Convergence Department, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea
| | - Yunjong Lee
- Division of Pharmacology, Department of Molecular Cell Biology, Samsung, Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Gyeonggi-do, 16419, Republic of Korea
| | - Sung-Gyu Park
- Nano-Bio Convergence Department, Korea Institute of Materials Science (KIMS), Changwon, 51508, Republic of Korea.
| | - Nae-Eung Lee
- School of Advanced Materials Science & Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea; SKKU Advanced Institute of Nanotechnology (SAINT), Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea; Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea; Institute of Quantum Biophysics (IQB), Sungkyunkwan University, Suwon, Gyeonggi-do, 16419, Republic of Korea; Biomedical Institute for Convergence at SKKU (BICS), Sungkyunkwa n University, Suwon, Gyeonggi-do, 16419, Republic of Korea.
| |
Collapse
|
3
|
Shi W, Li K, Zhang Y. The Advancement of Nanomaterials for the Detection of Hepatitis B Virus and Hepatitis C Virus. Molecules 2023; 28:7201. [PMID: 37894681 PMCID: PMC10608909 DOI: 10.3390/molecules28207201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 09/07/2023] [Accepted: 09/21/2023] [Indexed: 10/29/2023] Open
Abstract
Viral hepatitis is a global health concern mostly caused by hepatitis B virus (HBV) and hepatitis C virus (HCV). The late diagnosis and delayed treatment of HBV and HCV infections can cause irreversible liver damage and the occurrence of cirrhosis and hepatocellular carcinoma. Detecting the presence and activity of HBV and HCV is the cornerstone of the diagnosis and management of related diseases. However, the traditional method shows limitations. The utilization of nanomaterials has been of great significance in the advancement of virus detection technologies due to their unique mechanical, electrical, and optical properties. Here, we categorized and illustrated the novel approaches used for the diagnosis of HBV and HCV.
Collapse
Affiliation(s)
- Wanting Shi
- Interventional Therapy Center of Liver Disease, Beijing You’An Hospital, Capital Medical University, Beijing 100069, China;
| | - Kang Li
- Biomedical Information Center, Beijing You’An Hospital, Capital Medical University, Beijing 100069, China
| | - Yonghong Zhang
- Interventional Therapy Center of Liver Disease, Beijing You’An Hospital, Capital Medical University, Beijing 100069, China;
| |
Collapse
|